The Evolving Enterprise - The EE

Latest News

The EE assists Enterprises on their transformation journey by providing expert industry insights on the how’s, the where’s and the why’s, so procurement decisions can be made with confidence. We present deep, unbiased industry knowledge that couldn’t otherwise be found all in one place.

Quadric announces Llama2 LLM support for Chimera GPNPUs

Quadric has announced that support for Llama 2 large language model (LLM) is available on its Chimera general purpose neural processing unit (GPNPU) intellectual property (IP) core. Unlike other IP and semiconductor application processor suppliers, Quadric was able to add this support with a simple software port with no hardware changes, so existing designs can run this model. Other suppliers have announced plans to change their hardware to offer support in 2024 or beyond.

(more…)
Read more image/svg+xml

Intel recognises global winners of 3rd Annual AI Global Impact Festival

Intel announced global winners at its third annual AI Global Impact Festival. The festival brings together future developers, and educators who are working to solve real-world problems using artificial intelligence (AI), with support of policymakers and academic leaders. Students from 26 countries participated in competition at this year’s festival, “Enriching Lives with AI Innovation.” Intel’s event programme focused on building digital readiness for all students and celebrating AI innovations that drive inclusion, accessibility and responsible impact.

(more…)
Read more image/svg+xml

BenevolentAI, Merck join forces to utilise AI for drug discovery, from Hit ID to pre-clinical development

BenevolentAI announced that it has signed a collaboration with Merck. The collaboration will enable Merck to leverage BenevolentAI’s end-to-end AI (artificial intelligence) platform capabilities and gain access to a skillful team of interdisciplinary drug discovery scientists. This is done with aim of identifying and developing compounds, through hit identification (Hit ID) to pre-clinical stage.

(more…)
Read more image/svg+xml

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close